Cancer Chemotherapy and Pharmacology

Papers
(The H4-Index of Cancer Chemotherapy and Pharmacology is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
EVs delivery of miR-1915-3p improves the chemotherapeutic efficacy of oxaliplatin in colorectal cancer109
A clinical scoring tool validated with machine learning for predicting severe hand–foot syndrome from sorafenib in hepatocellular carcinoma29
Determination of 5-azacitidine in human plasma by LC–MS/MS: application to pharmacokinetics pilot study in MDS/AML patients26
Population pharmacokinetics of ruxolitinib in children with hemophagocytic lymphohistiocytosis: focus on the drug–drug interactions25
Quantitative proteomics profiling reveals the inhibition of trastuzumab antitumor efficacy by phosphorylated RPS6 in gastric carcinoma24
Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression24
Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with 4hydroxycyclophosphamide formation in children with Cancer24
Effects of cyclophosphamide related genetic variants on clinical outcomes of adult hematopoietic cell transplant patients23
A polo-like kinase 1 inhibitor enhances erastin sensitivity in head and neck squamous cell carcinoma cells in vitro23
Pharmacokinetics of cisplatin in the systemic versus hyperthermic intrathoracic or intraperitoneal chemotherapy23
Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study23
Correlation analysis between camrelizumab trough concentration levels and efficacy or safety in East Asian patients with advanced lung cancer21
Exposure–response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma20
Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide18
Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review18
UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells17
Plasma clearance of 5-fluorouracil is more influenced by variations in glomerular filtration rate than by uracil concentration17
Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations17
0.074031114578247